Controversies
Controversies tied to this brand in public sources. A listing is not a finding of fault.
Back to profile3 entries
2019
Pneumococcal vaccine pricing and supplier concentration
MSF argued that Gavi's pneumococcal procurement arrangements relied too heavily on GSK and Pfizer and that public subsidies had not produced sufficiently low prices. The issue also raised broader questions about pharmaceutical influence and governance conflicts.
2016
Debate over health-system-strengthening grants
Academic and civil-society assessments questioned whether Gavi's health-system funding was broad, sustainable and aligned with recipient-country priorities. Critics cited reporting burdens, short-term spending and a narrow reliance on vaccination coverage as a principal performance measure.
2012
Criticism of new-vaccine priorities
Médecins Sans Frontières criticized Gavi for directing substantial resources toward newer and more expensive vaccines while millions of children still lacked basic vaccines.